A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics

Sarepta Therapeutics SRPT underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $128.79, a high estimate of $224.00, and a low estimate of $40.00. Observing a downward trend, the current average is 15.39% lower than the prior average price target of $152.22.

Diving into Analyst Ratings: An In-Depth Exploration

A clear picture of Sarepta Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sarepta Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Sarepta Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Sarepta Therapeutics analyst ratings.

About Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics: Financial Performance Dissected

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Sarepta Therapeutics displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 44.1%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Sarepta Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.34% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Sarepta Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.44%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Sarepta Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.31%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Sarepta Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.79, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

Analyst Ratings: Simplified

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.